Thrombosis
Conference Coverage
VTE rates in lenalidomide-treated NHL may warrant prophylaxis
ATLANTA – Lenalidomide as single agent had twice the VTE rate as lenalidomide with a biologic.
Conference Coverage
Edoxaban noninferior to dalteparin for cancer-associated VTE
ATLANTA – Twelve months of daily edoxaban was noninferior to subcutaneous therapy with dalteparin for VTE in patients with cancer.
Conference Coverage
Emicizumab reduces bleeds in kids with hemophilia A and inhibitors
ATLANTA—Updated results from the HAVEN 2 trial have shown that emicizumab prophylaxis can reduce bleeds in children with hemophilia A and factor...
Conference Coverage
Guideline preview: ASH to recommend against VTE prophylaxis for lower-risk cancer patients
ATLANTA – ASH attendees got a preview of forthcoming recommendations on prevention and treatment of VTE in patients with cancer.
From the Journals
Poststroke depression raises risk of cerebrovascular death 35-fold
Depression after a stroke is deadly and should be monitored and treated.
Conference Coverage
Acute kidney injury linked with doubled inpatient VTEs
TORONTO – Which comes first: the acute kidney injury or the venous thromboembolism?
News
Procedure deemed unnecessary in most DVT patients
Researchers have found evidence to suggest that pharmacomechanical catheter-directed thrombolysis is largely inappropriate as first-line treatment...
News
Gene therapy seems safe, effective in hemophilia B
The gene therapy SPK-9001 has produced positive results in a phase 1/2 trial of adults with hemophilia B, according to researchers. SPK-9001...
From the Journals
Pharmacomechanical thrombolysis does not reduce post-thrombotic syndrome risk
The ATTRACT trial results contrast with recent reports from another randomized trial, known as CAVENT.
News
FDA approves use of heparin products
The US Food and Drug Administration (FDA) has approved use of Mylan NV’s heparin products. This includes Heparin Sodium Injection at 1000 USP/mL...
News
FDA grants priority review to NDA for avatrombopag
The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for avatrombopag. Avatrombopag is a...